Aldosterone may be the hidden culprit in hard-to-treat hypertension, offering new hope for targeted therapies. GORE TAG TBE receives FDA nod for Zones 0–1, expanding minimally invasive repair options for aortic arch lesions. Deepak Bhatt, MD, discusses EMPACT-MI findings on empagliflozin’s kidney safety and heart failure benefits after ACS. AI-powered cardiac MRI shows how aging impacts heart structure—and reveals hidden risks from common conditions. CKM syndrome redefines heart disease risk—90% of adults may already be affected. Learn why this new staging system matters. Patients experienced a median 57.6-month delay from first symptoms to ATTR-CM diagnosis, study finds. Black patients face higher amputation risk from PAD due to late CLTI care and limited access to revascularization. PVR severity is linked to higher short-term mortality in HFrEF, highlighting its role in risk stratification. AI-driven ECGs are transforming heart failure care—enabling early detection, cutting costs, and expanding access. Checklist use for ATTR-CM "red flags" boosted diagnosis rates up to 10x in heart failure patients, study finds. Heart failure affects over 640,000 kids and teens globally—urgent prevention and care policies are needed, study finds. Waist-to-height ratio may better predict heart failure risk than BMI, new Heart Failure 2025 study finds. Acoramidis rapidly boosts serum TTR levels in ATTR-CM patients, with effects sustained through 30 months, study shows. Dr. Payal Kohli dives into new tech and AI reshaping how we diagnose and manage hypertension. Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter. Women with maternal hypertension who birth preterm infants incur a risk for that child having adverse neurodevelopment. A multifaceted approach is necessary to reduce the deaths of smoking-related aortic aneurysms. Many preschool-aged children with congenital heart conditions are not on track for school readiness. A multicomponent intervention is effective in improving the management of people with high blood pressure, a study finds. Gender disparities persist in clinical trials related to atrial fibrillation (AF) management.